免疫性炎症与前列腺体积及雄激素受体表达的关系

目的：探讨免疫性炎症与前列腺体积及雄激素受体表达的关系。方法：回顾性的分析了105例手术获得的前列腺标本。使用免疫组化的方法研究前列腺纽织中CD4、CD8和雄激素受体表达情况。如果CD4或CD8阳性则敕定义为免疫性炎症,并进一步探讨了免疫性炎症与前列腺体积、雄激素受体表达之间的关系。结果：在前列腺增生组织中,CD4、CD8和雄激素受体表达的阳性率分别为20（19．0％）,21（20．0％）和48（45．7％）。在免疫性炎症组,前列腺体积为67．0±26．3ml,而在非免疫性炎症组,为54．0±24．2ml,有显著性差别。免疫性炎症组雄激素受体表达的阳性率为65．6％,而非免疫性炎症组雄激素受体表达的阳性率为37．0％（X2=7．35,P〈0．05）。结论：免疫性炎症与前列腺体积、雄激素受体表达明显相关。免疫性炎症可能导致前列腺增生进展,因此,抗炎治疗可能是治疗前列腺增生的一个新的靶点。     

CD147 在前列腺癌中的表达及其与肿瘤临床病理特征的关系

目的:研究CD147在还没前列腺癌组织中的表达及其与肿瘤临床病理特征的关系。方法:选择2013年10月-2015年10月我院收治的前列腺癌患者61例作为研究对象,另选取同期接受手术治疗的前列腺增生患者49例作为对照组,术中收集前列腺癌患者的肿瘤组织和癌旁组织以及前列腺增生患者的组织标本,采用免疫组化法检测CD147在前列腺癌组织、癌旁组织及前列腺增生组织中的表达情况。结果:CD147在前列腺癌组织中的阳性表达率(95.08%)显著高于癌旁组织(32.79%)和前列腺增生组织(16.32%),差异具有统计学意义(P0.05);CD147在癌旁组织中的阳性表达率(32.79%)高于前列腺增生组织(16.32%),差异具有统计学意义(P0.05)。CD147的阳性表达与前列腺癌Gleason分级、临床分期、淋巴结转移及远处转移呈正相关关系(P0.05)。结论:CD147在前列腺癌组织中呈阳性表达,且Gleason病理分级≥5、临床分期T3~4、淋巴结转移N1及远处转移M1均为前列腺癌组织中CD147m RNA阳性表达的危险因素。     

Cox-2、P504s、CK3413E12和P63在前列腺腺癌中的表达及其临床意义

目的:研究Cox-2、P504s、CK34βE12和P63在前列腺腺癌组织中的表达及其临床病理学意义.方法:用免疫组织化学法检测134例正常前列腺、良性前列腺增生和前列腺腺癌石蜡包埋组织中Cox-2、P504s、CK34βE12和P63的表达.结果:正常前列腺组织或良性前列腺增生组织未见或偶见P504s弱表达,但CK34βE12和P63均表达良好;前列腺腺癌组织中P504s表达良好,但CK34βE12和P63均表达消失,P504s表达阳性率为91.07%;与正常前列腺组和良性前列腺增生组相比.前列腺癌组的P504s阳性表达率存在显著性差异(p=0.001).COX-2在正常的前列腺组织几乎不表达,而良性前列腺增生组织及前列腺腺癌组织均可见阳性表达,阳性率分别为4.76%和80.36%;COX-2阳性表达率在正常前列腺组或良性前列腺增生组和前列腺腺癌组间有显著性差异(p=0.0027).COX-2与P504s表达存在相关性(r=0.377,P=0.039);COX-2的表达与年龄、临床分期、分化程度、有无远处转移等临床病理特征间无明显相关关系.结论:联合P504s、P63、CK34βE12和COX-2免疫组化检测可提高前列腺腺癌病理诊断的准确率.     

大鼠骨骼肌组织雄激素受体结合容量测定方法

目的 :以3H testosterone(T)为配基 ,测定大鼠骨骼肌胞浆中的雄激素受体结合容量。方法 :测定温度为 4℃ ,同位素配基的饱和浓度为 5 0 pmol/ml;肌组织以 4倍 (重量 /体积 )缓冲液稀释 ,0～ 4℃温度下 10 80 0 0×g离心 1h ;孵育 18～ 2 4h。结果 :骨骼肌中雄激素受体的Kd =2 ,8× 10 9mol/ml。单点法与多点法之间无显著区别。     

雷公藤甲素对哮喘豚鼠外周血CD_4~+和CD_8~+淋巴细胞的影响

探讨雷公藤甲素在治疗哮喘中对外周血 T淋巴细胞的影响机制 ,采用免疫细胞化学方法检测 30例豚鼠外周血淋巴细胞 CD+ 4 、 CD+ 8的表达。实验动物分为对照组、哮喘组和雷公藤甲素治疗组 (治疗组 ) ,每组各 1 0只。结果表明 ,治疗组CD+ 4 淋巴细胞表达阳性率及表达强度明显低于哮喘组 (P<0 .0 1 ) ,CD+ 8阳性率高于哮喘组 (P<0 .0 5 ) ,与对照组比较差异无显著性。本研究认为 ,雷公藤甲素可能通过增高哮喘豚鼠 CD+ 8淋巴细胞 ,降低 CD+ 4 淋巴细胞来发挥抗哮喘气道炎症作用。     

TAA 致慢性肝病内毒素血症大鼠清道夫受体、CD14 表达变化*

目的:观察清道夫受体(SR)和脂多糖受体CD14在TAA介导的慢性肝病内毒素血症大鼠肝组织中的表达。方法:通过大鼠持续灌胃给小剂量(12mg/kg.d)TAA建立大鼠肝损伤内毒素血症模型,HE染色光镜观察肝脏病理变化;改良赖氏法检测大鼠血清ALT、AST;改良过氯酸法测定血清内毒素含量;酶联免疫法检测大鼠血清CD4+和CD8+;免疫组化染色方法观察大鼠肝组织清道夫受体和CD14的表达。结果:TAA诱导后,大鼠肝脏出现片状坏死并可见灶性炎症;血浆ALT、AST及内毒素水平显著升高(P<0.05或P<0.01);血清CD4+、CD8+T细胞明显降低(P<0.01);肝组织CD14表达上调,清道夫受体表达下调,和正常大鼠相比,差异显著(P<0.05)。结论:肝组织SR表达下降和CD14表达增强可能是TAA介导慢性肝病内毒素血症的重要机制。     

良性前列腺增生患者外周血Th17和Treg细胞比率的变化

目的:探讨良性前列腺增生患者外周血Th17和Treg细胞比率的变化。方法:选择33例良性前列腺增生患者及19例正常对照者为研究对象,采用流式细胞术检测和比较其外周血中T淋巴细胞亚群及Th17和Treg细胞占CD4~+T细胞的比率。结果:良性前列腺增生患者外周血Th17和Treg细胞占CD4~+T细胞的比率分别为1.58±0.71和1.76±0.83,Th17/Treg的比率为0.89±0.42。正常健康对照者外周血Th17和Treg细胞占CD4~+T细胞的比率分别为0.75±0.46和1.83±0.75,Th17/Treg的比率为0.41±0.32。良性前列腺增生患者外周血Th17占CD4~+T细胞的比率和Th17/Treg的比率明显高于正常健康对照者(P0.05)。结论:良性前列腺增生患者体内Th17细胞比率升高,Th17/Treg比率失衡,可能与良性前列腺增生的发生、发展有关。     

老年癫痫患者血清miR-222、miR-21的水平变化及其临床意义

目的:探讨老年癫痫患者血清中miR-222、miR-21水平含量变化及其与炎症因子、T淋巴细胞亚群的关系。方法:选取2015年1月至2016年1月在我院诊断的老年癫痫患者47例(癫痫组)、选取同期健康体检对象47例作为健康组,检测两组血清miR-222、miR-21、肿瘤坏死因子-α(TNF-α)、白细胞介素-2(IL-2)、T淋巴细胞亚群水平,并分析相关性。结果:癫痫组的血清miR-222(1.2941±0.2751)、miR-21(2.1176±0.3382)、血清TNF-α(4.78±0.96)ng/m L、IL-2(4.37±1.12)ng/m L均高于健康组(0.6674±0.129)、(0.7314±0.1162)、(1.33±0.42)ng/m L、(8.96±2.77)ng/ml(P0.05);癫痫组的CD8+(28.92±3.16)%高于健康组(26.60±2.45)%(P0.05),CD4+(39.54±6.81)%、CD3+(57.18±7.44)%、CD4+/CD8+(1.37±0.20)均低于健康组(50.63±7.21)%、(69.25±6.81)%、(1.90±0.27)%(P0.05);癫痫组血清miR-222、miR-21与CD4+、CD3+水平呈显著的负相关性(r=-0.312,r=-0.381,P0.05),与患者的血清TNF-α、IL-2水平呈显著的正相关性(r=0.496,r=0.338,P0.05)。结论:老年癫痫患者血清中miR-222、miR-21水平显著的升高,并且与患者的血清炎症因子、T淋巴细胞水平变化有关,可能参与患者炎症反应及免疫水平的调节。     

根治性前列腺切除术后大体病理较术前穿刺病理升级的危险因素分析

目的:前列腺穿刺病理Gleason评分(GS)和根治性前列腺切除术后病理Gleason评分经常出现差异.本文主要研究肿瘤病理升级的可能影响因素.方法:选择1999-01至2007-11在本院行前列腺穿刺活检确诊并行根治性前列腺切除术的95例前列腺癌患者,考察的临床资料包括患者确诊时的年龄,前列腺特异性抗原水平(PSA),前列腺体积(PV),前列腺特异性抗原密度(PSAD),术前是否接受新辅助内分泌治疗(NHT),穿刺病理GS,手术后病理GS及肿瘤体积(TIV).使用t-检验或卡方检验比较不用组别之间的变量,分别使用单因素和多因素Logistical回归分析引起GS升级的相关因素.结果:患者的平均年龄是67岁,平均PSA水平为24.3 ng/ml,平均前列腺体积是33.1ml.将前列腺体积分为≤25ml(25例),25-50ml(59例),≥50ml(11例)三组,将穿刺病理GS分为4-5(13例),6(35例),7(32例),8-10(15例)四组.前列腺体积较大组(≥50m1)比体积较小组(≤25ml,25-50m1)的肿瘤升级比率明显较低(48% vs 24%,18%,p＜0.05).穿刺病理GS较高组(8-10)比较低组(4-5,6,7)的肿瘤升级比率明显减低(46% vs 34%,25%,13%,p＜0.05).多因素Logistic回归分析显示,PV、穿刺GS及内分泌治疗与病理升级呈负相关(p＜0.05),而肿瘤体积及PSAD与其呈正相关(p＜0.05).结论:较大的前列腺体积,较高的穿刺病理GS,接受内分泌治疗以及较低的PSAD均可降低其肿瘤升级的可能.泌尿外科医师在决定由穿刺活检确诊的前列腺癌患者的治疗方案时应想到上述结论.     

前列腺癌组织及PC-3细胞中STAT3及磷酸化STAT3的表达

目的　研究前列腺癌组织及前列腺癌细胞株PC- 3 中STAT3 蛋白及磷酸化STAT3 蛋白的表达。方法　常规石蜡包埋切片SABC免疫组化法检测45例前列腺癌组织、20例前列腺增生组织中STAT3 及磷酸化STAT3 表达, 细胞免疫化学法检测前列腺癌细胞株PC 3细胞STAT3及磷酸化STAT3表达。结果　STAT3在前列腺癌及前列腺增生组织表达阳性率分别为77. 8%和50. 0%, 两者间具有显著差异; 磷酸化STAT3在前列腺癌及前列腺增生组织表达阳性率分别为68. 9%和35. 0%, 两者间具显著差异(P<0 .05); PC- 3细胞中STAT3及磷酸化STAT3表达阳性。结论　STAT3蛋白在前列腺癌中高表达且持续激活, 可能与前列腺癌的发生具有密切联系。     

Transforming growth factor beta 1 and androgen receptors in prostate neoplasia

OBJECTIVE: To investigate the interplay between transforming growth factor (TGF) beta 1, androgen receptors and stromal-epithelial interactions in benign prostatic hyperplasia (BPH), prostate intraepithelial neoplasia (PIN) and prostate carcinoma areas of prostate neoplasia. STUDY DESIGN: In this immunohistochemical study we investigated staining patterns and then determined the correlation between TGF-beta 1 expression and androgen receptor status in the epithelium and stroma of 60 paraffin-embedded tissues from radical prostatectomies. RESULTS: Staining patterns differed in the epithelium and stroma of tumor and peritumor prostatic tissue. TGF-beta 1 immunostaining (H-scores) in the epithelium and stroma increased significantly from BPH to PIN and from BPH to prostate carcinoma in the epithelium (P < .05), whereas androgen receptor (AR) immunoreactivity significantly (P < .05) increased from BPH to PIN to prostatic carcinoma in epithelium and stroma. TGF-beta 1 did not correlate with histologic grade of differentiation, whereas AR proteins were more strongly expressed in Gleason score 5 and 6 than score 7 tumors (P < .05). Nonlinear regression showed a significant correlation (P < .01) between TGF-beta 1 and AR expression only in the stromal compartment of PIN. CONCLUSION: These findings argue in favor of an interaction between TGF-beta 1 and AR in the early stages of prostate carcinogenesis and suggest that TGF-beta 1 plays a central role in stromal-epithelial interactions during the early stages of malignant transformation.     

Role of stromal tenascin-C in mouse prostatic development and epithelial cell differentiation

Deregulation of epithelial-stromal interactions is considered to play a critical role in the initiation and promotion of benign prostatic hyperplasia (BPH) and prostate carcinoma (PCa). Expression of tenascin-C (TN-C), an extracellular matrix (ECM) glycoprotein, is reportedly higher in BPH and PCa as compared with normal prostate. Remodeling of the ECM alters the homeostatic balance between epithelium and stroma, resulting in physiological changes in cellular functions. To investigate the role of TN-C in prostatic development and differentiation, we evaluated the morphological phenotype of TN-C knockout (KO) mouse prostate (ventral: VP, dorsolateral: DLP, and anterior: AP) and examined tissue recombinants composed of adult mouse DLP epithelium and fetal TN-C KO urogenital sinus mesenchyme (UGM). Histological analysis showed epithelial cell clusters protruding into the ductal lumens in TN-C KO AP and DLP. Interestingly, binucleated cells appeared in epithelium of TN-C KO DLP at 8 weeks. Simultaneously, androgen receptor (AR)-positive cells were decreased in TN-C KO epithelia. Similar to the TN-C KO phenotype, protruded epithelial clusters, binucleated cells, and AR-negative nuclei were induced in DLP epithelium by recombining with TN-C KO UGM. Our results suggest that stromal TN-C might be involved in maintaining epithelial cytodifferentiation, morphogenesis, and androgen receptor expression of normal prostate glands in adult mice.     

Binding of [3H] methyltrienolone (R 1881) in rat prostate and human benign prostatic hypertrophy (BPH).

Methyltrienolone (R 1881 - 17beta-hydroxy-17alpha-methyl-estra-4, 9, 11-trien-3-one) binding to rat ventral prostate cytosol has a specificity typical of an androgen receptor. In human benign prostatic hypertrophy (BPH) tissue, the specificity of [3H] R 1881 binding is different from that measured in rat prostate: progesterone and R 5020 (17, 21-dimethyl-19-nor-4, 9-pregnadiene-3, 20-dione) being more potent while 19-nortestosterone is less potent competitor. Moreover, the synthetic progestin [3H] R 5020 binds to BPH tissue with a similar specificity. These data suggest the presence of progestin binding components or of an atypical androgen receptor in human BPH cytosol.     

Increased infiltrated macrophages in benign prostatic hyperplasia (BPH): role of stromal androgen receptor in macrophage-induced prostate stromal cell proliferation

Infiltrated macrophages may play important roles in the development and progression of benign prostatic hyperplasia (BPH), but the underlying mechanisms remain largely unknown. We found increased macrophages infiltration in human and mouse BPH tissues. By establishing a co-culture transwell system, we found increased migration of macrophages and proliferation of prostate stromal cells during co-culture. Importantly, stromal androgen receptor (AR) could enhance the migration of macrophages and macrophage-mediated stromal cell proliferation. We identified CCL3 as an AR downstream player, and found CCL3 levels were notably increased in human and mouse BPH prostates. Ablation of prostate stromal AR in a mouse BPH model significantly reduced CCL3 expression levels in prostates. Consistently, targeting AR via an AR degradation enhancer, ASC-J9§, or neutralization of CCL3 with an antibody, resulted in suppression of macrophage migration and prostate stromal cell growth. Our study provides mechanistic insights on the regulation of prostate stromal cells by macrophages via stromal AR/CCL3 signaling pathways, which could potentially allow the development of therapeutic approaches for battling BPH with persistent inflammation.     

Sex steroid receptor expression and localization in benign prostatic hyperplasia varies with tissue compartment

Androgens and estrogens, acting via their respective receptors, are important in benign prostatic hyperplasia (BPH). The goals of this study were to quantitatively characterize the tissue distribution and staining intensity of androgen receptor (AR) and estrogen receptor-alpha (ERα), and assess cells expressing both AR and ERα, in human BPH compared to normal prostate. A tissue microarray composed of normal prostate and BPH tissue was used and multiplexed immunohistochemistry was performed to detect AR and ERα. We used a multispectral imaging platform for automated scanning, tissue and cell segmentation and marker quantification. BPH specimens had an increased number of epithelial and stromal cells and increased percentage of epithelium. In both stroma and epithelium, the mean nuclear area was decreased in BPH relative to normal prostate. AR expression and staining intensity in epithelial and stromal cells was significantly increased in BPH compared to normal prostate. ERα expression was increased in BPH epithelium. However, stromal ERα expression and staining intensity was decreased in BPH compared to normal prostate. Double positive (AR and ERα) epithelial cells were more prevalent in BPH, and fewer double negative (AR and ERα) stromal and epithelial negative cells were observed in BPH. These data underscore the importance of tissue layer localization and expression of steroid hormone receptors in the prostate. Understanding the tissue-specific hormone action of androgens and estrogens will lead to a better understanding of mechanisms of pathogenesis in the prostate and may lead to better treatment for BPH.     

Adénome prostatique, hormones et androgénothérapie

The prostate is an androgen dependent organ. Benign prostatic hyperplasia (BPH) has a high prevalence in histological studies, but all the affected men do not present symptoms. Aging and the presence of androgens are the main determinants of BPH. However, androgen blood levels were not higher in patients with BPH than in the general population. Suppression of androgens induced a decrease in prostatic volume. Androgen replacement therapy resulted in a re-increase of prostatic volume, but during androgen replacement therapy the prostate volume was only slighty increased, it any, thus remaining within normal range. The present review of the literature indicates that BPH is no a contra-indication for androgen replacement therapy in men with partial or complete androgen deficiency. However, it must be noticed that in most of the studies published so far subjects with BPH have been excluded. A specific study involving such patients is to be undertaken.     

Androgens and estrogens in benign prostatic hyperplasia: past, present and future

Benign prostatic hyperplasia (BPH) and associated lower urinary tract symptoms (LUTS) are common clinical problems in urology. While the precise molecular etiology remains unclear, sex steroids have been implicated in the development and maintenance of BPH. Sufficient data exists linking androgens and androgen receptor pathways to BPH and use of androgen reducing compounds, such as 5α-reductase inhibitors which block the conversion of testosterone into dihydrotestosterone, are a component of the standard of care for men with LUTS attributed to an enlarged prostate. However, BPH is a multifactorial disease and not all men respond well to currently available treatments, suggesting factors other than androgens are involved. Testosterone, the primary circulating androgen in men, can also be metabolized via CYP19/aromatase into the potent estrogen, estradiol-17β. The prostate is an estrogen target tissue and estrogens directly and indirectly affect growth and differentiation of prostate. The precise role of endogenous and exogenous estrogens in directly affecting prostate growth and differentiation in the context of BPH is an understudied area. Estrogens and selective estrogen receptor modulators (SERMs) have been shown to promote or inhibit prostate proliferation signifying potential roles in BPH. Recent research has demonstrated that estrogen receptor signaling pathways may be important in the development and maintenance of BPH and LUTS; however, new models are needed to genetically dissect estrogen regulated molecular mechanisms involved in BPH. More work is needed to identify estrogens and associated signaling pathways in BPH in order to target BPH with dietary and therapeutic SERMs.     

Diabetes, growth hormone-insulin-like growth factor pathways and association to benign prostatic hyperplasia

Diabetes significantly increases the risk of benign prostatic hyperplasia (BPH) and low urinary tract symptoms (LUTS). The major endocrine aberration in connection with the metabolic syndrome is hyperinsulinemia. Insulin is an independent risk factor and a promoter of BPH. Insulin resistance may change the risk of BPH through several biological pathways. Hyperinsulinemia stimulates the liver to produce more insulin-like growth factor (IGF), another mitogen and an anti-apoptotic agent which binds insulin receptor/IGF receptor and stimulates prostate growth. The levels of IGFs and IGF binding proteins (IGFBPs) in prostate tissue and in blood are associated with BPH risk, with the regulation of circulating androgen and growth hormone. Stromal-epithelial interactions play a critical role in the development and growth of the prostate gland and BPH. Previously, we have shown that the expression of c-Jun in the fibroblastic stroma can promote secretion of IGF-I, which stimulates prostate epithelial cell proliferation through activating specific target genes. Here, we will review the epidemiologic, clinical, and molecular findings which have evaluated the relation between diabetes and development of BPH.